We are addressing a high unmet medical need in circulatory shock
We are developing a targeted therapy to modulate a major shock pathway
Advancing critical care management and paving the way toward precision medicine
Supported by
The project is funded by the European Social Fund (ESF) and the Federal State of Brandenburg via the Brandeburg Ministry for Labor, Social Affairs, Health, Women and Family (MASGF).
Septic and Cardiogenic Shock
are the most common forms of circulatory shock among patients in ICU
| Sepsis is affecting almost 50 million people worldwide every year. |
| Septic shock kills half of the patients in intensive care units. |
| Cardiogenic shock mortality rate exceeds 70% in intensive care units. |
We identify and stratify high risk patients using our established biomarker
Dipeptidyl Peptidase 3 is an important causative pathway in septic and cardiogenic shock
We are developing a targeted therapy to inhibit DPP3
Procizumab will be a first-in-class antibody targeting the DPP3 pathway in septic & cardiogenic shock.
Our Investors
News
11.04.2022
Dipeptidyl peptidase 3 biomarker to drive precision medicine in COVID-19
.
05.01.2022
The emerging role of dipeptidyl peptidase 3 in pathophysiology
.
16.09.2020
transkript: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis
15.05.2020
News Medical: High DPP3 concentration in the blood predicts multiple organ failure in burn patients
14.05.2020
European Biotechnology: 4TEEN4’s DPP3 predicts burn mortality
08.01.2020
Biopharmapress: Combating Sepsis Mortality
06.01.2020
European Biotechnology: Fighting sepsis mortality
05.12.2019
BioWorld: 4TEEN4 closes $8M A round to test first-in-class cardiogenic shock drug
.
11.04.2022
Dipeptidyl peptidase 3 biomarker to drive precision medicine in COVID-19
.
11.04.2022
Dipeptidyl peptidase 3 biomarker to drive precision medicine in COVID-19
.
25.03.2022
DPP3 predicts organ failure and in-hospital mortality in postoperative patients
01.02.2022
DPP3 biomarker to advance prediction of organ function progression in septic patients
.
16.09.2020
4TEEN4’s first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis
05.01.2022
The emerging role of dipeptidyl peptidase 3 in pathophysiology
.
04.01.2022
Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?
.
01.01.2022
Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis
.
08.12.2021
High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort.
.
24.08.2021
Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality
..
01.06.2021
Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome
.
01.06.2021
Circulating biomarkers to assess cardiovascular function in critically ill
.
15.03.2021
Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage
21.02.2021
Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study.
30.12.2020
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.
20.11.2020
In-hospital mortality and organ failure after open and endovascular thoraco-abdominal aortic surgery can be predicted by increased levels of circulating dipeptidyl peptidase 3.